Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability

References

• Ross R. Mechanisms of disease – atherosclerosis – an inflammatory disease. N. Engl. J. Med.340, 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Newby AC. Dual role of matrix metalloproteinases (matrixins) in neointima formation and atherosclerotic plaque rupture. Physiol. Rev.85, 1–31 (2005).
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behaviour. Annu. Rev. Cell. Dev. Biol.17, 463–516 (2001).
   PubMed Web of Science ®Google Scholar
• Nagase H, Barrett AJ, Woessner JF. Nomenclature and glossary of the matrix metalloproteinases. Matrix Suppl.1, 421–424 (1992).
   PubMedGoogle Scholar
• Sato H, Takin T, Okada Y et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature370, 61–65 (1994).
   PubMed Web of Science ®Google Scholar
• Hernandez-Barrantes S, Bernardo M, Toth M, Fridman R. Regulation of membrane type-matrix metalloproteinases. Cancer Biol.12, 131–138 (2002).
   PubMed Web of Science ®Google Scholar
• Somerville RPT, Oblander SA, Apte SS. Matrix metalloproteinases: old dogs with new tricks. Genome Biol.4, 1–11 (2003).
   Web of Science ®Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res.69, 562–573 (2006).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Qin H, Lin L, Tan EM. Basic fibroblast growth factor regulates type I collagen and collagenase gene expression in human smooth muscle cells. Am. J. Pathol.146, 764–771 (1995).
   PubMed Web of Science ®Google Scholar
• Pickering JG, Ford CM, Tang B, Chow LH. Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells – evidence for repressed collagen production and activated degradative capacity. Arterioscler. Thromb. Vasc. Biol.17, 475–482 (1997).
   PubMed Web of Science ®Google Scholar
• Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NF-κB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc. Res.50, 556–565 (2001).
   PubMed Web of Science ®Google Scholar
• Galis ZS, Muszynski M, Sukhova GK et al. Cytokine-stimulated human vascular smooth muscle synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res.75, 181–189 (1994).
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro – implications for atherosclerotic plaque stability. J. Clin. Invest.98, 2572–2579 (1996).
   PubMed Web of Science ®Google Scholar
• George SJ, Zaltsman AB, Newby AC. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc. Res.33, 447–459 (1997).
   PubMed Web of Science ®Google Scholar
• Schönbeck U, Mach F, Sukhova GK et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by lymphocytes. A role for CD40 signaling in plaque rupture? Circ. Res.81, 448–454 (1997).
   Google Scholar
• Stawowy P, Meyborg H, Stibenz D et al. Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis. Circulation111, 2820–2827 (2005).
   PubMed Web of Science ®Google Scholar
• Galis ZS, Muszynski M, Sukhova GK et al. Cytokine-stimulated human vascular smooth muscle synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res.75, 181–189 (1994).
   PubMed Web of Science ®Google Scholar
• Fabunmi RP, Baker AH, Murray EJ, Booth RFG, Newby AC. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1,-2 and -3 in rabbit aortic smooth muscle cells. Biochem. J.315, 335–342 (1996).
   PubMed Web of Science ®Google Scholar
• Chase AJ, Bond M, Crook MF, Newby AC. Role of nuclear factor-kB activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler. Thromb. Vasc. Biol.22, 765–771 (2002).
   PubMed Web of Science ®Google Scholar
• Gurjar MV, DeLeon J, Sharma RV, Bhalla RC. Mechanism of inhibition of matrix metalloproteinase-9 induction by NO in vascular smooth muscle cells. J. Appl. Physiol.91, 1380–1386 (2001).
   PubMed Web of Science ®Google Scholar
• Lutgens E, Daemen MJAP. Transforming growth factor-β. A local or sytemic mediator of plaque stability? Circ. Res.89, 853–855 (2001).
   PubMed Web of Science ®Google Scholar
• Lacraz S, Nicod L, Galve-de Rochemonteix B, Baumberger C, Dayer JM, Welgus HG. Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J. Clin. Invest.90, 382–388 (1992).
   PubMed Web of Science ®Google Scholar
• Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest.96, 2304–2310 (1995).
   PubMed Web of Science ®Google Scholar
• Shapiro SD, Campbell EJ, Kobayashi DK, Welgus HG. Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-γ. J. Clin. Invest.86, 1204–1210 (1990).
   PubMed Web of Science ®Google Scholar
• Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc. Res.59, 812–823 (2003).
   PubMed Web of Science ®Google Scholar
• Chase AJ, Newby AC. Regulation of matrix metalloproteinase (Matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. J. Vasc. Res.40, 329–343 (2003).
   PubMed Web of Science ®Google Scholar
• Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol.19, 623–629 (2000).
   PubMed Web of Science ®Google Scholar
• Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br. Heart J.73, 209–215 (1995).
   PubMedGoogle Scholar
• Jormsjo S, Wahtling C, Walter DH, Zeiher AM, Hamsten A, Eriksson P. Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol.21, 1834–1839 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang B, Ye S, Herrmann S-M et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation99, 1788–1794 (1999).
   PubMed Web of Science ®Google Scholar
• Jormsjo S, Ye S, Moritz J et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ. Res.86, 998–1003 (2000).
   PubMed Web of Science ®Google Scholar
• Nagase H. Activation mechanisms of matrix metalloproteinases. Biol. Chem.378, 151–160 (1997).
   PubMed Web of Science ®Google Scholar
• Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature375, 244–247 (1995).
   PubMed Web of Science ®Google Scholar
• Pei D, Kang T, Qi H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a Type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem.275, 33988–33997 (2000).
   PubMed Web of Science ®Google Scholar
• Illman SA, Keski-Oja J, Parks WC, Lohi J. The mouse matrix metalloproteinase, epilysin (MMP-28), is alternatively spliced and processed by a furin-like proprotein convertase. Biochem. J.375, 191–197 (2003).
   PubMed Web of Science ®Google Scholar
• Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb. Haemost.86, 324–333 (2001).
   PubMed Web of Science ®Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Circ. Res.93, 827–839 (2003).
   Google Scholar
• Murphy G, Willenbrock F, Crabbe T et al. Regulation of matrix metalloproteinase activity. In: Inhibition of Matrix Metalloproteinases: Therapeutic Potential. Greenwald RA, Golub LM (Eds). NY Acad Sci, NY, USA 31–41 (1994).
   Google Scholar
• Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell-surface activation of 72 kDa type IV collagenase - isolation of the activated form of membrane metalloprotease. J. Biol. Chem.270, 5331–5339 (1995).
   PubMed Web of Science ®Google Scholar
• Itoh Y, Takamura A, Ito N et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J.20, 4782–4793 (2001).
   PubMed Web of Science ®Google Scholar
• Maquoi E, Frankenne F, Noel A, Krell H-W, Grams F, Foidart J-M. Type IV collagen induces matrix metalloproteinase 2 activation in HT1080 fibrosarcoma cells. Exp. Cell. Res.261, 348–359 (2001).
   Web of Science ®Google Scholar
• Nie J, Pei D. Direct activation of pro-matrix metalloproteinase-1 by leukolysin/membrane-type 6 matrix metalloproteinase/matrix metalloproteinase 25 at the Asn109-Tyr bond. Cancer Res.63, 6758–6762 (2003).
   PubMed Web of Science ®Google Scholar
• Nagase H, Woessner JF. Matrix metalloproteinases. J. Biol. Chem.274, 21491–21494 (1999).
   PubMed Web of Science ®Google Scholar
• Ellerbroek SM, Wu YI, Overall CM, Stack MS. Functional interplay between Type I collagen and cell surface matrix metalloproteinase activity. J. Biol. Chem.276, 24833–24842 (2001).
   PubMed Web of Science ®Google Scholar
• Knauper V, Bailey L, Worley JR, Soloway P, Patterson ML, Murphy G. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett.532, 127–130 (2002).
   PubMed Web of Science ®Google Scholar
• Gruber BL, Marchese MJ, Suzuki K et al. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J. Clin. Invest.84, 1657–1662 (1989).
   PubMed Web of Science ®Google Scholar
• Lees M, Taylor DJ, Woolley DE. Mast cell proteinases activate precursor of collagenase and stromelysin but not of gelatinases A and B. Eur. J. Biochem.223, 171–177 (1994).
   PubMedGoogle Scholar
• Saarinen J, Kalkkinen N, Welgus H, Kovanen PT. Activation of human interstitial pro-collagenase through direct cleavage of the Leu83-Thr84 bond by mast cell chymase. J. Biol. Chem.269, 18134–18140 (1994).
   PubMed Web of Science ®Google Scholar
• Suzuki K, Lees M, Newlands GFJ, Nagase H, Woolley DE. Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Biochem. J.305, 301–306 (1995).
   PubMed Web of Science ®Google Scholar
• Johnson JL, Jackson CL, Angelini GD, George SJ. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol.18, 1707–1715 (1998).
   PubMed Web of Science ®Google Scholar
• McCawley LJ, Matrisian LM. Matrix metalloproteinases: they’re not just for matrix anymore! Curr. Opin. Cell. Biol.13, 534–540 (2001).
   PubMed Web of Science ®Google Scholar
• Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem.271, 10079–10086 (1996).
   PubMed Web of Science ®Google Scholar
• Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-β 1 release. Biochem. J.322, 809–814 (1997).
   PubMed Web of Science ®Google Scholar
• Vogel W. Discoidin domain receptors: structural relations and functional implications. FASEB J.13, S77–S82 (1999).
   PubMed Web of Science ®Google Scholar
• Franco CD, Hou G, Bendeck MP. Collagens, integrins, and the discoidin domain receptors in arterial occlusive disease. Trends Cardiovasc. Med.12, 143–148 (2002).
   PubMed Web of Science ®Google Scholar
• Carmichael DF, Sommer A, Thompson RC et al. Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. Proc. Natl Acad. Sci. USA83, 2407–2411 (1986).
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson WG, Krutzch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J. Biol. Chem.264, 17374–17378 (1989).
   PubMed Web of Science ®Google Scholar
• Wick M, Bürger C, Brüsselbach S, Lucibello FC, Müller R. A novel member of human tissue inhibitor of metalloproteinases (TIMP) gene family is regulated during G1 progression, mitogenic stimulation, differentiation, and senescence. J. Biol. Chem.269, 18953–18960 (1994).
   PubMed Web of Science ®Google Scholar
• Greene J, Wang MS, Liu YLE, Raymond LA, Rosen C, Shi YNE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J. Biol. Chem.271, 30375–30380 (1996).
   PubMed Web of Science ®Google Scholar
• Fassina G, Ferrari N, Brigati C et al. Tissue inhibitors of metalloproteases: regulation and biological activities. Clin. Exp. Metastasis18, 111–120 (2000).
   PubMed Web of Science ®Google Scholar
• Fridman R, Fuerst TR, Bird RE et al. Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J. Biol. Chem.267, 15398–15405 (1992).
   PubMed Web of Science ®Google Scholar
• Bigg HF, Shi YE, Liu YE, Steffensen B, Overall CM. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. J. Biol. Chem.272, 15496–15500 (1997).
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Sato H, Akiko et al. TIMP-2 promotes activation of progelatinase a by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J. Biol. Chem.273, 16098–16103 (1998).
   PubMed Web of Science ®Google Scholar
• Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J. Biol. Chem.269, 9352–9360 (1994).
   PubMed Web of Science ®Google Scholar
• Overall CM. Regulation of tissue inhibitor of matrix metalloproteinase expression. In: Inhibition of Matrix Metalloproteinases: Therapeutic Potential. Greenwald RA, Golub LM (Eds). NY Acad Sci, NY, USA 51–64 (1994).
   Google Scholar
• Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. FEBS Lett.298, 29–32 (1992).
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell. Sci.107, 2373–2379 (1994).
   PubMed Web of Science ®Google Scholar
• Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell. Physiol.157, 351–8 (1993).
   PubMed Web of Science ®Google Scholar
• Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell. Sci.115, 3719–3727 (2002).
   PubMed Web of Science ®Google Scholar
• Bond M, Murphy G, Bennett MR et al. Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. J. Biol. Chem.275, 41358–41363 (2000).
   PubMed Web of Science ®Google Scholar
• Bond M, Murphy G, Bennett MR, Newby AC, Baker AH. Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent Type II apoptotic pathway. J. Biol. Chem.277, 13787–13795 (2002).
   PubMed Web of Science ®Google Scholar
• Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood92, 1342–1349 (1998).
   PubMed Web of Science ®Google Scholar
• Valente P, Fassina G, Melchiori A et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer75, 246–253 (1998).
   PubMed Web of Science ®Google Scholar
• Herman MP, Sukhova GK, Kisiel W et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J. Clin. Invest.107, 1117–1126 (2001).
   PubMed Web of Science ®Google Scholar
• Borth W. α-2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J.6, 3345–3353 (1992).
   PubMed Web of Science ®Google Scholar
• Oh J, Takahashi R, Kondo S et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell107, 789–800 (2001).
   PubMed Web of Science ®Google Scholar
• Pederson DC, Bowyer DE. Endothelial injury and healing in vitro – studies using an organ-culture system. Am. J. Pathol.119, 264–272 (1985).
   PubMed Web of Science ®Google Scholar
• Soyombo AA, Angelini GD, Bryan AJ, Jasani B, Newby AC. Intimal proliferation in an organ culture of human saphenous vein. Am. J. Pathol.137, 1401–1410 (1990).
   PubMed Web of Science ®Google Scholar
• Izzard TD, Taylor C, Birkett SD, Jackson CL, Newby AC. Mechanisms underlying maintenance of smooth muscle cell quiescence in rat aorta: role of the cyclin dependent kinases and their inhibitors. Cardiovasc. Res.53, 242–252 (2002).
   PubMed Web of Science ®Google Scholar
• Jawien A, Bowen-Pope DF, Linder V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest.89, 507–511 (1992).
   PubMed Web of Science ®Google Scholar
• Fingerle J, Kraft T. The induction of smooth muscle cell proliferation in vitro using an organ culture system. Int. Angio.6, 65–72 (1987).
   PubMed Web of Science ®Google Scholar
• Soyombo AA, Angelini GD, Bryan AJ, Newby AC. Surgical preparation induces injury and promotes smooth muscle cell proliferation in a culture of human saphenous vein. Cardiovasc. Res.27, 1961–1967 (1993).
   PubMed Web of Science ®Google Scholar
• Chai YC, Binion DG, Macklis R, Chisolm GM. Smooth muscle cell proliferation induced by oxidized LDL-borne lysophosphatidyleholine – evidence for FGF-2 release from cells not extracellular matrix. Vasc. Pharmacol.38, 229–237 (2002).
   PubMed Web of Science ®Google Scholar
• Southgate KM, Fisher M, Banning AP et al. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ. Res.79, 1177–1187 (1996).
   PubMed Web of Science ®Google Scholar
• Johnson JL, Van Eys GJJM, Angelini GD, George SJ. Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein. Arterioscler. Thromb. Vasc. Biol.21, 1146–1151 (2001).
   PubMed Web of Science ®Google Scholar
• Auge N, Maupas-Schwalm F, Elbaz M et al. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation110, 571–578 (2004).
   PubMed Web of Science ®Google Scholar
• Campbell JH, Campbell GR. Endothelial-cell influences on vascular smooth-muscle phenotype. Annu. Rev. Physiol.48, 295–306 (1986).
   PubMed Web of Science ®Google Scholar
• Hedin U, Bottger BA, Forsberg E, Johansson S, Thyberg J. Diverse effects of fibronectin and laminin on phenotypic properties of cultured arterial smooth muscle cells. J. Cell Biol.107, 307–319 (1988).
   PubMed Web of Science ®Google Scholar
• Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem. J.288, 93–99 (1992).
   PubMed Web of Science ®Google Scholar
• Gilbertson-Beadling SK, Fisher C. A potential role for N-cadherin in mediating endothelial cell-smooth muscle-cell interactions in the rat vasculature. Lab. Invest.69, 203–209 (1993).
   PubMed Web of Science ®Google Scholar
• Tetsu O, McCormick F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature.398, 422–426 (1999).
   PubMed Web of Science ®Google Scholar
• He TC, Sparks AB, Rago C et al. Identification of c-MYC as a target of the APC pathway. Science281, 1509–1512 (1998).
   PubMed Web of Science ®Google Scholar
• Crawford HC, Fingleton BM, Rudolph-Owen LA et al. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene18, 2883–2891 (1999).
   PubMed Web of Science ®Google Scholar
• Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y. Identification of membrane-type matrix metalloproteinase-1 as a target of the β-catenin/Tcf4 complex in human colorectal cancers. Oncogene21, 5861–5867 (2002).
   PubMed Web of Science ®Google Scholar
• Uglow EB, Slater S, Sala-Newby GB et al. Dismantling of cadherin-mediated cell–cell contacts modulates smooth muscle cell proliferation. Circ. Res.92, 1314–1321 (2003).
   PubMed Web of Science ®Google Scholar
• Slater SC, Koutsouki E, Jackson CL et al. R-cadherin: β-catenin complex and its association with vascular smooth muscle cell proliferation. Arterioscler. Thromb. Vasc. Biol.24, 1204–1210 (2004).
   PubMed Web of Science ®Google Scholar
• Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ. Res.91, 845–851 (2002).
   PubMed Web of Science ®Google Scholar
• Bingley JA, Hayward IP, Campbell JH, Campbell GR. Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J. Vasc. Surg.28, 308–318 (1998).
   PubMed Web of Science ®Google Scholar
• Kinsella MG, Tran PK, Weiser-Evans MCM, Reidy M, Majack RA, Wight TN. Changes in perlecan expression during vascular injury – role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler. Thromb. Vasc. Biol.23, 608–614 (2003).
   PubMed Web of Science ®Google Scholar
• Aguilera CM, George SJ, Johnson JL, Newby AC. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. Cardiovasc. Res.58, 679–688 (2003).
   PubMed Web of Science ®Google Scholar
• Morla AO, Mogford JE. Control of smooth muscle cell proliferation and phenotype by integrin signaling through focal adhesion kinase. Biochem. Biophys. Res. Comm.272, 298–302 (2000).
   PubMed Web of Science ®Google Scholar
• Schwartz MA, Assoian RK. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J. Cell. Sci.114, 2553–2560 (2001).
   PubMed Web of Science ®Google Scholar
• Walker HA, Whitelock JM, Garl PJ, Nemenoff RA, Stenmark KR, Weiser-Evans MCM. Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol. Biol. Cell14, 1941–1952 (2003).
   PubMed Web of Science ®Google Scholar
• Lucchesi PA, Sabri A, Belmadani S, Matrougui K. Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries. Circulation110, 3587–3593 (2004).
   PubMed Web of Science ®Google Scholar
• Hollenbeck ST, Sakakibara K, Faries PL, Workhu B, Liu B, Kent KC. Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway. J. Surg. Res.120, 288–294 (2004).
   PubMed Web of Science ®Google Scholar
• Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Thromb. Vasc. Biol.16, 28–33 (1996).
   PubMed Web of Science ®Google Scholar
• Lovdahl C, Thyberg J, Hultgardh-Nilsson A. The synthetic metalloproteinase inhibitor batimistat suppresses injury-induced phosphorylation of MAP kinase ERK1/ERK2 and phenotypic modification of arterial smooth muscle cells in vitro. J. Vasc. Res.37, 345–354 (2000).
   PubMed Web of Science ®Google Scholar
• Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. Doxycyline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am. J. Pathol.160, 1089–1095 (2002).
   PubMed Web of Science ®Google Scholar
• Islam MM, Franco CD, Courtman DW, Bendeck MP. A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening. Am. J. Pathol.163, 1557–1566 (2003).
   PubMed Web of Science ®Google Scholar
• Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ. Res.78, 38–43 (1996).
   PubMed Web of Science ®Google Scholar
• Galis ZS, Johnson C, Godin D et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ. Res.91, 852–859 (2002).
   PubMed Web of Science ®Google Scholar
• Lovdahl C, Thyberg J, Cercek B et al. Antisense oligonucleotides to stromelysin mRNA inhibit injury-induced proliferation of arterial smooth muscle cells. Histol. Histopathol.14, 1101–1112 (1999).
   PubMed Web of Science ®Google Scholar
• George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits SMC migration and neointima formation in human saphenous vein. Hum. Gene Ther.9, 867–877 (1998).
   PubMed Web of Science ®Google Scholar
• George SJ, Baker AH, Angelini GD, Newby AC. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther.5, 1552–1560 (1998).
   PubMed Web of Science ®Google Scholar
• Cheng L, Mantile G, Pauly R et al. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation98, 2195–2201 (1998).
   PubMed Web of Science ®Google Scholar
• Dollery CM, Humphries SE, McClelland A, Latchman DS, McEwan JR. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation99, 3199–3205 (1999).
   PubMed Web of Science ®Google Scholar
• George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation101, 296–304 (2000).
   PubMed Web of Science ®Google Scholar
• Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. J. Clin. Invest.101, 1478–1487 (1998).
   PubMed Web of Science ®Google Scholar
• Pauly RR, Passaniti A, Bilato C et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ. Res.75, 41–54 (1994).
   PubMed Web of Science ®Google Scholar
• Haque NS, Fallon JT, Pan JJ, Taubman MB, Harpel PC. Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. Blood103, 1296–1304 (2004).
   PubMed Web of Science ®Google Scholar
• Mason DP, Kenagy RD, Hasenstab D et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle migration and alters remodeling in the injured rat carotid artery. Circ. Res.85, 1179–1185 (1999).
   PubMed Web of Science ®Google Scholar
• Filippov S, Koenig GC, Chun T-H et al. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J. Exp. Med.5, 663–671 (2005).
   Google Scholar
• Kuzuya M, Kanda S, Sasaki T et al. Deficiency of gelatinase A suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation108, 1375–1381 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson C, Galis ZS. Matrix metalloproteinase-2 and-9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler. Thromb. Vasc. Biol.24, 54–60 (2004).
   PubMed Web of Science ®Google Scholar
• Moiseeva EP. Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovasc. Res.52, 372–386 (2001).
   PubMed Web of Science ®Google Scholar
• Ang AH, Tachas G, Campbell JH, Bateman JF, Campbell GR. Collagen-synthesis by cultured rabbit aortic smooth-muscle cells – alteration with phenotype. Biochem. J.265, 461–469 (1990).
   PubMed Web of Science ®Google Scholar
• Thyberg J. Differentiated properties and proliferation of arterial smooth muscle cells in culture. In: International Review of Cytology – a Survey of Cell Biology.169, 183–265 (1996).
   Google Scholar
• Thyberg J, Blomgren K, Roy J, Tran PK, Hedin U. Phenotypic modulation of smooth muscle cells after arterial injury is associated with changes in the distribution of laminin and fibronectin. J. Histochem. Cytochem.45, 837–846 (1997).
   PubMed Web of Science ®Google Scholar
• Carragher NO, Frame MC. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell. Biol.14, 241–249 (2004).
   PubMed Web of Science ®Google Scholar
• Stringa E, Knauper V, Murphy G, Gavrilovic J. Collagen degradation and platelet-derived growth factor stimulate the migration of vascular smooth muscle cells. J. Cell. Sci.113, 2055–2064 (2000).
   PubMed Web of Science ®Google Scholar
• Stringa E, White D, Tuan RS, Knauper V, Gavrilovic J. Role of newly synthesized fibronectin in vascular smooth muscle cell migration on matrix-metalloproteinase-degraded collagen. Biochem. Soc.30(Pt 2), 102–106 (2002).
   PubMed Web of Science ®Google Scholar
• Bendeck MP, Irvin C, Reidy M et al. Smooth muscle cell matrix metalloproteinase production is stimulated via α(v)β(3) integrin. Arterioscler. Thromb. Vasc. Biol.20, 1467–1472 (2000).
   PubMed Web of Science ®Google Scholar
• Varadarajulu J, Laser M, Hupp M, Wu RX, Hauck CR. Targeting of α(V) integrins interferes with FAK activation and smooth muscle cell migration and invasion. Biochem. Biophys. Res. Comm.331, 404–412 (2005).
   PubMed Web of Science ®Google Scholar
• Shofuda T, Shofuda K, Ferri N, Kenagy RD, Raines EW, Clowes AW. Cleavage of focal adhesion kinase in vascular smooth muscle cells overexpressing membrane-type matrix metalloproteinases. Arterioscler. Thromb. Vasc. Biol.24, 839–844 (2004).
   PubMed Web of Science ®Google Scholar
• Carragher NO, Levkau B, Ross R, Raines EW. Degraded collagen fragments promote rapid disassembly of smooth muscle focal adhesions that correlates with cleavage of pp125(FAK), paxillin and talin. J. Cell Biol.147, 619–629 (1999).
   PubMed Web of Science ®Google Scholar
• Isacke CM, Yarwood H. The hyaluronan receptor, CD44. Int. J. Biochem. Cell Biol.34, 718–721 (2002).
   PubMed Web of Science ®Google Scholar
• Kajita M, Itoh Y, Chiba T et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol.153, 893–904 (2001).
   PubMed Web of Science ®Google Scholar
• Suenaga N, Mori H, Itoh Y, Seiki M. CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene24, 859–868 (2005).
   PubMed Web of Science ®Google Scholar
• Yu WH, Woessner JF, McNeish JD, Stamenkovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Develop.16, 307–323 (2002).
   PubMed Web of Science ®Google Scholar
• Mori H, Tomari T, Koshikawa N et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J.21, 3949–3959 (2002).
   PubMed Web of Science ®Google Scholar
• Abecassis I, Olofsson B, Schmid M, Zalcman G, Karniguian A. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp. Cell Res.291, 363–376 (2003).
   PubMed Web of Science ®Google Scholar
• Zempo N, Kenagy RD, Au T et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid. J. Vasc. Surg.20, 209–217 (1994).
   PubMed Web of Science ®Google Scholar
• Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res.75, 539–545 (1994).
   PubMed Web of Science ®Google Scholar
• Pinney SP, Chen HJ, Liang DX, Wang XY, Schwartz A, Rabbani LE. Minocycline inhibits smooth muscle cell proliferation, migration and neointima formation after arterial injury. J. Cardiovasc. Pharmacol.42, 469–476 (2003).
   PubMed Web of Science ®Google Scholar
• Yao JHS, Chen YM, Zhai WW, Xu KY, Young WL, Yang GY. Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration – the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ. Res.95, 364–371 (2004).
   PubMed Web of Science ®Google Scholar
• Franco C, Ho B, Mulholland D et al. Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices. Am. J. Pathol.168, 1697–1709 (2006).
   PubMed Web of Science ®Google Scholar
• Forough R, Koyama N, Hasenstab D et al. Overexpression of tissue inhibitor of matrix metalloprotienase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ. Res.79, 812–820 (1996).
   PubMed Web of Science ®Google Scholar
• Furman C, Luo Z, Walsh K et al. Systemic tissue inhibitor of metalloproteinase-1 gene delivery reduces neointimal hyperplasia in balloon-injured rat carotid artery. FEBS Lett.531, 122–126 (2002).
   PubMed Web of Science ®Google Scholar
• Lijnen HR, Soloway P, Collen D. Tissue inhibitor of matrix metalloproteinase-1 impairs arterial neointima formation after vascular injury in mice. Circ. Res.85, 1186–1191 (1999).
   PubMed Web of Science ®Google Scholar
• Stoneman VEA, Bennett MR. Role of apoptosis in atherosclerosis and its therapeutic implications. Clin. Sci.107, 343–354 (2004).
   PubMed Web of Science ®Google Scholar
• von der Thusen JH, van Vlijmen BJM, Hoeben RC et al. Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation105, 2064–2070 (2002).
   PubMed Web of Science ®Google Scholar
• Mercer J, Figg N, Stoneman V, Braganza DM, Bennett MR. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ. Res.96, 667–674 (2005).
   PubMed Web of Science ®Google Scholar
• Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ. Res.94, 68–76 (2004).
   PubMed Web of Science ®Google Scholar
• Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation112, 423–431 (2005).
   PubMed Web of Science ®Google Scholar
• Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-β 1 release. Biochem. J.322, 809–814 (1997).
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Larsen L, Engsig MT et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-β controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J. Biol. Chem.277, 44061–44067 (2002).
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Yano K, Sugimoto S et al. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res.64, 665–671 (2004).
   PubMed Web of Science ®Google Scholar
• Levkau B, Kenagy RD, Karsan A et al. Activation of metalloproteinases and their association with integrins: an auxillary apoptotic pathway in human endothelial cells. Cell Death Diff.9, 136–1367 (2002).
   Google Scholar
• Ilic D, Almeida EAC, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J. Cell Biol.143, 547–560 (1998).
   PubMed Web of Science ®Google Scholar
• Almeida EAC, Ilic D, Han Q et al. Matrix survival signaling: From fibronectin via focal adhesion kinase to c-Jun NH2-terminal kinase. J. Cell Biol.149, 741–754 (2000).
   PubMed Web of Science ®Google Scholar
• Wallner K, Li C, Shah PK, Wu K-J, Schwartz SM, Sharifi BG. EGF-like domain of tenascin-C is proapoptotic for cultured smooth muscle cells. Arterioscler. Thromb. Vasc. Biol.24, 1–6 (2004).
   Google Scholar
• Lipinski KV, Keul P, Lucke S et al. Degraded collagen induces calpain-mediated apoptosis and destruction of the X-chromosome-linked inhibitor of apoptosis (xIAP) in human vascular smooth muscle cells. Cardiovasc. Res.69, 697–705 (2006).
   PubMed Web of Science ®Google Scholar
• Koutsouki E, Beeching CA, Slater SC, Blaschuk OW, Sala-Newby GB, George SJ. N-cadherin-dependent cell-cell contacts promote human saphenous vein smooth muscle cell survival. Arterioscler. Thromb. Vasc. Biol.25, 982–988 (2005).
   PubMed Web of Science ®Google Scholar
• Wu WB, Huang TF. Activation of MMP-2, cleavage of matrix proteins, and adherens junctions during a snake venom metalloproteinase-induced endothelial cell apoptosis. Exp. Cell Res.288, 143–157 (2003).
   PubMed Web of Science ®Google Scholar
• Strand S, Vollmer P, van den Abeelen L et al. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene23, 3732–3736 (2004).
   PubMed Web of Science ®Google Scholar
• Mannello F, Luchetti F, Falcieri E, Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis10, 19–24 (2005).
   PubMed Web of Science ®Google Scholar
• Geng Y-J, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler. Thromb. Vasc. Biol.22, 1370–1380 (2002).
   PubMed Web of Science ®Google Scholar
• Smith MR, Kung HF, Durum SK, Colburn NH, Sun Y. TIMP-3 induces cell death by stabilizing TNF-α receptors on the surface of human colon carcinoma cells. Cytokine9, 770–780 (1997).
   PubMed Web of Science ®Google Scholar
• Bian JH, Wang YL, Smith MR et al. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis17, 1805–1811 (1996).
   PubMed Web of Science ®Google Scholar
• Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br. J. Cancer70, 1347–1355 (1999).
   Google Scholar
• Guo YH, Gao W, Li Q, Li PF, Yao PY, Chen KH. Tissue inhibitor of metalloproteinases-4 suppresses vascular smooth muscle cell migration and induces cell apoptosis. Life Sci.75, 2483–2493 (2004).
   PubMed Web of Science ®Google Scholar
• Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest.94, 2493–2503 (1994).
   PubMed Web of Science ®Google Scholar
• Galis ZS, Sukhova GK, Libby P. Microscopic localisation of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J.9, 974–980 (1995).
   PubMed Web of Science ®Google Scholar
• Li Z, Li L, Zielke HR et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am. J. Pathol.148, 121–128 (1996).
   PubMed Web of Science ®Google Scholar
• Halpert I, Sires UI, Roby JD et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc. Natl Acad. Sci. USA93, 9748–9753 (1996).
   PubMed Web of Science ®Google Scholar
• Schönbeck U, Mach F, Sukhova GK et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J. Exp. Med.189, 843–853 (1999).
   PubMed Web of Science ®Google Scholar
• Sukhova GK, Schonbeck U, Rabkin E et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation.99, 2503–2509 (1999).
   PubMed Web of Science ®Google Scholar
• Rajavashisth TB, Xu X-P, Jovinge S et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. Circ. Res.99, 3101–3109 (1999).
   Google Scholar
• Uzui H, Harpf A, Liu M et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque. Role of activated macrophages and inflammatory cytokines. Circ. Res.106, 3024–3030 (2002).
   Google Scholar
• Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc. Res.69, 625–635 (2006).
   PubMed Web of Science ®Google Scholar
• Major TC, Liang L, Lu X, Rosebury W, Bocan TMA. Extracellular matrix metalloproteinase induced (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler. Thromb. Vasc. Biol.22, 1200–1207 (2002).
   PubMed Web of Science ®Google Scholar
• Schmidt R, Bultmann A, Ungerer M et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells. Circulation.113, 834–841 (2006).
   PubMed Web of Science ®Google Scholar
• Janssens S, Lijnen HR. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cardiovasc. Res.69, 585–594 (2006).
   PubMed Web of Science ®Google Scholar
• Lemaître V, O’Byrne TK, Borczuk AC, Okada Y, Tall AR, D’Armiento J. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J. Clin. Invest.107, 1227–1234 (2001).
   PubMed Web of Science ®Google Scholar
• Deguchi JO, Aikawa E, Libby P et al. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation.112, 2708–2715 (2005).
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Deguchi J, Libby P et al. Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. Circulation.110, 1953–1959 (2004).
   PubMed Web of Science ®Google Scholar
• Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler. Thromb. Vasc. Biol.21, 1440–1445 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases -3, -7, -9 and -12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc. Natl Acad. Sci. USA102, 15575–15580 (2005).
   PubMed Web of Science ®Google Scholar
• Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem.271, 13055–13060 (1996).
   PubMed Web of Science ®Google Scholar
• Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol.26, 1120–1125 (2006).
   PubMed Web of Science ®Google Scholar
• Luttun A, Lutgens E, Manderveld A et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation.109, 1408–1414 (2004).
   PubMed Web of Science ®Google Scholar
• Choi ET, Collins ET, Marine LA et al. Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for injury-induced accelerated atherosclerotic plaque development in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol.25, 1020–1025 (2005).
   PubMed Web of Science ®Google Scholar
• de Nooijer R, Verkleij CJ, von der Thuesen JH et al. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions, but not at earlier stages of atherogenesis. Arterioscler. Thromb. Vasc. Biol.26, 340–346 (2006).
   PubMed Web of Science ®Google Scholar
• Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Invest.116, 59–69 (2006).
   PubMed Web of Science ®Google Scholar
• Liang J, Liu E, Yu Y et al. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation.113, 1993–2001 (2006).
   PubMed Web of Science ®Google Scholar
• Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl Acad. Sci. USA93, 3942–3946 (1996).
   PubMed Web of Science ®Google Scholar
• Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ. Res.90, 897–903 (2002).
   PubMed Web of Science ®Google Scholar
• Lemaître V, Soloway PD, D’Armiento J. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation107, 333–338 (2003).
   PubMed Web of Science ®Google Scholar
• Rouis M, Adamy C, Duverger N et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation100, 533–540 (1999).
   PubMed Web of Science ®Google Scholar
• Johnson JL, Baker AH, Oka K et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: Involvement of macrophage migration and apoptosis. Circulation113, 2435–2444 (2006).
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv. Dent. Res.12, 12–26 (1998).
   PubMedGoogle Scholar
• Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol.23, 483–488 (2003).
   PubMed Web of Science ®Google Scholar
• Prescott MF, Sawyer WK, Von Linden-Reed J et al. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann. NY Acad. Sci.878, 179–190 (1999).
   PubMed Web of Science ®Google Scholar
• Johnson JL, Fritsche-Danielson R, Behrendt M et al. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc. Res.71, 586–595 (2006).
   PubMed Web of Science ®Google Scholar
• Cherr GS, Motew SJ, Travis JA et al. Metalloproteinase inhibition and the response to angioplasty and stenting in atherosclerotic primates. Arterioscler. Thromb. Vasc. Biol.22, 161–166 (2002).
   PubMed Web of Science ®Google Scholar
• Brown DL, Desai KK, Vakili BA, Nouneh C, Lee H-M, Golub LM. Clinical and biochemical results of the Metalloproteinase Inhibition with subantimicrobial Doses of doxycycline to prevent Acute coronary Syndromes (MIDAS) pilot trial. Arterioscler. Thromb. Vasc. Biol.24, 733–738 (2004).
   PubMed Web of Science ®Google Scholar
• Axisa B, Loftus IM, Naylor AR et al. prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke33, 2858–2864 (2002).
   PubMed Web of Science ®Google Scholar
• Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res.69, 677–687 (2006).
   PubMed Web of Science ®Google Scholar
• Luan Z, Chase AJ, Newby AC. Statins Inhibit secretion of metalloproteinases-1,-2, -3 and -9 from vascular smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol.23, 769–775 (2003).
   PubMed Web of Science ®Google Scholar
• Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME. Simvastatin promotes atherosclerotic plaque stability in ApoE-deficient mice independently of lipid lowering. Arterioscler. Thromb. Vasc. Biol.22, 1832–1837 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson J, Carson K, Williams H et al. Plaque rupture after short periods of fat-feeding in the apolipoprotein E knockout mouse: model characterisation, and effects of pravastatin treatment. Circulation111, 1422–1430 (2005).
   PubMed Web of Science ®Google Scholar
• Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases and cell death in human carotid plaques. Circulation103, 926–933 (2001).
   PubMed Web of Science ®Google Scholar
• Son JW, Koh KK, Ahn JY et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int. J. Cardiol.88, 77–82 (2003).
   PubMed Web of Science ®Google Scholar